Fulgent Genetics, Inc. (FLGT): Price and Financial Metrics


Fulgent Genetics, Inc. (FLGT): $54.65

-0.19 (-0.35%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

FLGT POWR Grades


  • FLGT scores best on the Sentiment dimension, with a Sentiment rank ahead of 88.03% of US stocks.
  • FLGT's strongest trending metric is Growth; it's been moving down over the last 179 days.
  • FLGT ranks lowest in Stability; there it ranks in the 4th percentile.

FLGT Stock Summary

  • With a price/earnings ratio of 3.88, Fulgent Genetics Inc P/E ratio is greater than that of about only 3.48% of stocks in our set with positive earnings.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.16 for Fulgent Genetics Inc; that's greater than it is for only 11.13% of US stocks.
  • As for revenue growth, note that FLGT's revenue has grown 135.37% over the past 12 months; that beats the revenue growth of 94.09% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to Fulgent Genetics Inc, a group of peers worth examining would be CVLT, MIME, CTXS, EPAY, and PHR.
  • Visit FLGT's SEC page to see the company's official filings. To visit the company's web site, go to www.fulgentgenetics.com.

FLGT Valuation Summary

  • FLGT's price/sales ratio is 3; this is 21.05% lower than that of the median Healthcare stock.
  • Over the past 60 months, FLGT's price/sales ratio has gone down 13.3.
  • Over the past 60 months, FLGT's EV/EBIT ratio has gone up 22.7.

Below are key valuation metrics over time for FLGT.

Stock Date P/S P/B P/E EV/EBIT
FLGT 2021-08-31 3.0 3.0 5.5 4.0
FLGT 2021-08-30 3.0 3.0 5.5 4.0
FLGT 2021-08-27 3.0 3.0 5.6 4.1
FLGT 2021-08-26 3.1 3.1 5.7 4.2
FLGT 2021-08-25 3.1 3.1 5.7 4.2
FLGT 2021-08-24 3.0 3.0 5.6 4.1

FLGT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • FLGT has a Quality Grade of C, ranking ahead of 74.39% of graded US stocks.
  • FLGT's asset turnover comes in at 1.214 -- ranking 12th of 81 Healthcare stocks.
  • MGLN, UHS, and ADUS are the stocks whose asset turnover ratios are most correlated with FLGT.

The table below shows FLGT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 1.214 0.793 1.237
2021-03-31 1.514 0.793 1.595
2020-12-31 1.489 0.787 1.426
2020-09-30 1.037 0.692 0.646
2020-06-30 0.522 0.559 0.028
2020-03-31 0.472 0.565 -0.007

FLGT Price Target

For more insight on analysts targets of FLGT, see our FLGT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $103.00 Average Broker Recommendation 1.5 (Moderate Buy)

FLGT Stock Price Chart Interactive Chart >

Price chart for FLGT

FLGT Price/Volume Stats

Current price $54.65 52-week high $112.00
Prev. close $54.84 52-week low $47.34
Day low $54.08 Volume 230,400
Day high $55.56 Avg. volume 431,838
50-day MA $54.07 Dividend yield N/A
200-day MA $71.04 Market Cap 1.66B

Fulgent Genetics, Inc. (FLGT) Company Bio


Fulgent Genetics, Inc., a technology company, focuses on providing genetic testing services to physicians with clinically actionable diagnostic information. It intends to provide tests to hospitals and medical institutions. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. The company was founded in 2011 and is based in Temple City, California.


FLGT Latest News Stream


Event/Time News Detail
Loading, please wait...

FLGT Latest Social Stream


Loading social stream, please wait...

View Full FLGT Social Stream

Latest FLGT News From Around the Web

Below are the latest news stories about Fulgent Genetics Inc that investors may wish to consider to help them evaluate FLGT as an investment opportunity.

Fulgent, Epic Sciences collaborate on test for metastatic breast cancer

Epic Sciences is collaborating with Fulgent Genetics (FLGT -5.9%) to deliver DefineMBC profiling results for patients with metastatic breast cancer (MBC). The partnership links Fulgent's CAP/CLIA certified next generation sequencing services with Epic's cell analysis platform as part of Epic's novel DefineMBC liquid biopsy test. The companies said the DefineMBC includes...

Seeking Alpha | February 24, 2022

EPIC SCIENCES AND FULGENT GENETICS COLLABORATE TO DELIVER DefineMBC™ RESULTS FOR METASTATIC BREAST CANCER PATIENTS

Epic Sciences, Inc. today announced it has partnered with Fulgent Genetics (NASDAQ:FLGT) to deliver DefineMBC comprehensive profiling results for metastatic breast cancer (MBC) patients. The partnership links Fulgent's leading CAP/CLIA certified Next Generation Sequencing services with Epic's best-in-class cell analysis platform as part of Epic's novel DefineMBC liquid biopsy test.

Yahoo | February 24, 2022

Fulgent Genetics Non-GAAP EPS of $3.48 beats by $0.81, revenue of $251.7M beats by $60.6M

Fulgent Genetics press release (NASDAQ:FLGT): Q4 Non-GAAP EPS of $3.48 beats by $0.81. Revenue of $251.7M beats by $60.6M. Shares -5%. Outlook Q1 2022:T otal Revenue of approximately $245 million; Core Revenue including COVID-19 NGS of approximately $32 million, representing growth of 92% year-over-year; Core Revenue excluding COVID-19 NGS of approximately $22 million...

Seeking Alpha | February 23, 2022

Fulgent Genetics Reports Fourth Quarter and Full Year 2021 Financial Results

TEMPLE CITY, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics,” “Fulgent,” or the “Company”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced financial results for its fourth quarter and full year ended December 31, 2021. Fourth Quarter 2021 Results: Revenue of $251.7 million Billable tests delivered approximately 2.5 million Core Revenue grew 234%

Business Wire | February 23, 2022

Fulgent Genetics, Inc. (FLGT) CEO Ming Hsieh on Q4 2021 Results - Earnings Call Transcript

No summary available.

Seeking Alpha | February 23, 2022

Read More 'FLGT' Stories Here

FLGT Price Returns

1-mo 0.26%
3-mo -12.60%
6-mo -45.67%
1-year -40.75%
3-year 781.45%
5-year 755.24%
YTD -45.67%
2021 93.07%
2020 303.88%
2019 306.94%
2018 -27.63%
2017 -62.14%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7108 seconds.